$Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy$

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy

Although most differentiated thyroid cancers show excellent prognosis, treating radioiodine refractory differentiated thyroid cancer (RR-DTC) is challenging. Various therapies, including chemotherapy, radiotherapy, and targeted therapy, have been applied for RR-DTC but show limited effectiveness. Re...

Full description

Bibliographic Details
Main Authors:	Chae Moon Hong, Byeong-Cheol Ahn
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-10-01
Series:	Frontiers in Endocrinology
Subjects:	redifferentiation differentiated thyroid cancer I-131 radioiodine refractory NIS
Online Access:	http://journal.frontiersin.org/article/10.3389/fendo.2017.00260/full

Similar Items

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer
by: Yoon Ju Choi, et al.
Published: (2021-01-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Aplicaciones clínicas del radioyodo 131 (I131) en las enfermedades del tiroides Clinical applications of radioiodine 131 (I131) in the thyroid diseases
by: Levi González Rivero, et al.
Published: (2012-12-01)

Autonomous Functioning Thyroid Nodule in a 4-year-old Male Child Treated with Radioiodine (I-131)
by: Abhishek Khare, et al.
Published: (2013-01-01)

Original paper<br>Effects of absorbed dose of 131I isotope on the effectiveness of ablation of thyroid remnant tissue
by: Zbigniew Adamczewski, et al.
Published: (2007-06-01)

The Side Effects of Therapeutic Radioiodine-131 on the Structure of Enamel and Dentin in Permanent Human Teeth
by: Alexandru Mester, et al.
Published: (2021-04-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
by: Mohamed Aashiq, et al.
Published: (2019-09-01)

Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone
by: G.J. Paz-Filho, et al.
Published: (2007-12-01)

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
by: Yuchen Jin, et al.
Published: (2017-11-01)

Unusual false positive radioiodine uptake on 131 I whole body scintigraphy in three unrelated organs with different pathologies in patients of differentiated thyroid carcinoma: A case series
by: Rohit Ranade, et al.
Published: (2016-01-01)

“Tumour sink effect” on the diagnostic or posttreatment radioiodine scan due to sequestration into large-volume functioning metastasis of differentiated thyroid carcinoma influencing uptake in smaller metastatic sites or remnant thyroid tissue: An uncommon but possible phenomenon in thyroid cancer practice
by: Sandip Basu, et al.
Published: (2020-01-01)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
by: Lorusso L, et al.
Published: (2016-10-01)

Efficacy of single fixed dose of radioiodine (I-131) therapy in patients with hyperthyroidism at Groote Schuur Hospital
by: Isah, Ahmed Rufai
Published: (2020)

Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?
by: Elizabeth J. de Koster, et al.
Published: (2021-03-01)

<sup>18</sup>F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
by: Freba Ahmaddy, et al.
Published: (2021-01-01)

Potential of the drug-regulation iodide uptake in patients for prevention of radioiodine-refractory papillary thyroid cancer
by: Dmitriy Kirillovich Fomin, et al.
Published: (2014-11-01)

Measurement of Radiation Exposure to Caregivers of Patients with Thyroid Diseases Treated with Iodine-131: A Review
by: Ali Abdulhasan Kadhim, et al.
Published: (2020-09-01)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
by: Ajit S Shinto, et al.
Published: (2013-01-01)

CYTOLOGICAL CHARACTERISTICS OF POSTOPERATIVE METASTASES OF PAPILLARY THYROID CANCER DURING THE DEVELOPMENT OF SECONDARY RADIOIODINE REFRACTORINESS
by: Anna Zelinskaya, et al.
Published: (2020-01-01)

Radioiodine therapy activity 550 MBq of I131 in thyrotoxicosis patients
by: Marina S. Sheremeta, et al.
Published: (2016-10-01)

Evaluation of Discordance in Differentiated Thyroid Cancer Patients with Negative Radioiodine Scans and Positive Thyroglobulin Values at the Ablation Outcome Control
by: Zeynep Gözde Özkan, et al.
Published: (2012-03-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
by: Alexandru Mester, et al.
Published: (2020-11-01)

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
by: Carla Colombo, et al.
Published: (2020-11-01)

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer
by: Tremblay G, et al.
Published: (2016-06-01)

177Lu-DOTATATE and177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment
by: Majid Assadi, et al.
Published: (2019-01-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
by: Zohreh Maghsoomi, et al.
Published: (2021-05-01)

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis
by: Yu S, et al.
Published: (2019-02-01)

A rare case of minimally invasive follicular thyroid cancer with intraluminal superior vena cava and right atrium metastases
by: Alex Cheen Hoe Khoo, et al.
Published: (2019-01-01)

Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy
by: Mariya Alekseevna Karalkina, et al.
Published: (2015-07-01)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
by: Lv RB, et al.
Published: (2017-08-01)

Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia
by: Ivan I. Dedov, et al.
Published: (2018-12-01)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
by: Jiang HJ, et al.
Published: (2021-09-01)

Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey
by: Christoph Reiners, et al.
Published: (2020-07-01)

Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer
by: C Chiapponi, et al.
Published: (2021-09-01)

Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma
by: Le Ngoc Ha, et al.
Published: (2021-01-01)

Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan
by: Chen-Yuan Lin, et al.
Published: (2021-01-01)